Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD - Kempsford, Rodger; Norris, Virginia; Siederer, Sarah (Pulmonary pharmacology & therapeutics, 2013)
Keywords: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists - therapeutic use; Adult; Aged; Asthma; Asthma - drug therapy; Asthma - physiopathology; Benzyl Alcohols - adverse effects; Benzyl Alcohols - therapeutic use; Blood Glucose - analysis; Bronchodilator Agents - therapeutic use; Chlorobenzenes - adverse effects; Chlorobenzenes - therapeutic use; COPD; Electrocardiography; Female; Forced Expiratory Volume - drug effects; Heart Rate - drug effects; Humans; Male; Medical Education; Middle Aged; Pharmacodynamics; Pharmacokinetics; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - physiopathology; Pulmonary/Respiratory; Vilanterol; β2-agonist; Vilanterol; Pharmacodynamics; Pharmacokinetics; β2-agonist; COPD; Asthma